Advances in eye care. Connections to experts.


35TH ANNUAL EYE EDUCATION FOUNDATION SYMPOSIUM **HUGE SUCCESS!** Our planning team looks forward to this event

from the Southeast who attended this year's Seminar. Attendees had the opportunity to earn 20 credit hours and learn from an excellent lineup of nationally renowned speakers. We celebrated two long-time attendees, Dr. Michael Raim and Dr. Gavin McFaden for achieving the impressive milestone of 50 Years in practice. We traveled back to the 80's for some nostalgic fun. Attendees enjoyed classic arcade games, a live DJ and specialty multi-colored signature cocktails. The Eye Center South Leadership team joined in the selfie station fun.

all year! Thank you to over 120 Optometrists









you missed! https://www.facebook.com/EyeEducationFoundation. While you're there, click "Follow" for updates leading up to next year's event or visit us at <u>www.eyeeducationfoundation.net</u>. Follow us on Facebook @EyeEducationFoundation for updates throughout the year.



CLINIC NEWS

DR. MARIUS HEERSINK JOINS

DOTHAN CLINIC THIS SUMMER.

Dr. Marius Heersink will join the Dothan clinic medical staff this August. He recently completed his residency at Wills Eye Institute in Philadelphia,

Pennsylvania with a focus on Comprehensive ophthalmology, cornea, and refractive surgery. In 2020 he earned his Dual Medical Doctorate (MD) and Master of Business Administration (MBA) from the UAB Heersink School of Medicine and Collat School of Business in Birmingham, Alabama. He completed his B.S. at UAB, graduating Summa Cum Lauda through the Early Medical School Acceptance Program. He is eager to join his father and brother in the Dothan practice, and to meet each of you. We will host a reception to introduce him to the local medical community. Stay tuned for an invitation. We will also be making




personal visits to Dothan area optometry offices to provide opportunities for you to get to know him better. Please join us in giving Dr. Marius Heersink a warm welcome back home to Dothan! ECS-DESTIN EARNS VIP DESTIN MAGAZINE "BEST OF DESTIN" AWARD


Destin" award for "Best Eye Care Clinic" for the 6th year in a row! Jackie Williamson recently attended the VIP Destin Magazine Black Tie Gala at the San Destin Hilton to receive our

community continues to support us as their top choice for quality specialty eyecare. OD/MD EDUCATIONAL

ECS-Destin recently received the 2024 "Best of

award. We are honored that the Destin






Chris co-sponsored by Johnson and

Johnson. Dr. Bansagi enjoyed sharing

for more educational events like this

one in Destin in the coming months.

"Advances in Intraocular Lenses." Look





iDose TR is a new, FDA approved treatment

that is designed to provide long duration, continuous drug therapy directly inside the eye, helping patients take better control over the elevated eye pressure associated with Sebastian B. Heersink, M.D. Cataract & Laser Refractive open-angle glaucoma or ocular hypertension. Surgeon & Cornea Specialist

Developed by Glaukos, iDose TR reduces high or elevated pressure within

the eye by automatically releasing the same type of medication used for

study, 8 out of 10 patients did not need prescription eye drops 12 months

after administration of iDose TR. iDose TR may be particularly beneficial


decades in the most commonly prescribed eye drops. During a clinical

Invitations to follow.

PHYSICIAN NEWS

for patients who have difficulty adhering to a daily medication regimen or whose condition is uncontrolled on topical glaucoma medications. "Eye Center South is dedicated to providing our patients with the most advanced treatment options available," said Dr. Sebastian Heersink for Eye Center South. "iDose TR represents a significant development in how we can proactively address glaucoma care, and we are proud to be among the first practices in the State of Alabama to make this therapy available." If you have patients who would benefit from this new treatment, please contact us for an appointment at our Dothan clinic.

81%



https://www.idosetrhcp.com/about-idose/ Clinically Proven with Foundational IOP Control In two pivotal trials, iDose TR achieved the pre-specified primary efficacy endpoint (non-inferiority to topical timolol through 3 months). At 12 months:

of iDose TR subjects were completely free

of IOP-lowering topical medication¹

two robust pivotal trials therapeutic levels of a proprietary formulation of travoprost intracamerally


Demonstrated long-term IOP control in

24/7 Adherence with iDose TR

iDose TR is a paradigm-changing treatment.


1986 and has enjoyed a long successful career in

Designed to deliver continuous






Provides proven safety and patient tolerability



DR. BENNETT ANNOUNCES





Ophthalmology. He is loved by his medical

family, and patients. He is well known for

his respected career this summer.



800-467-1393 · EyeCenterSouth.net